Superworth

LENSAR free cash flow LNSR

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Dec 31, 2025
−$14.9M
Latest quarter, Q4 FY25
$618K
−83% on a year earlier
Fiscal year 2025
−$14.9M

LENSAR's free cash flow was −$14.9M over the twelve months to Dec 31, 2025.

In its latest quarter, Q4 FY25, it was $618K, down 83% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$14.9Mn/a
FY2024−$2.4Mn/a
FY2023−$9.9Mn/a
FY2022−$15Mn/a
FY2021−$9.3Mn/a
FY2020−$14.2Mn/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY25$618K−83%−$14.9M
Q3 FY25−$3.5M−212%−$11.9M
Q2 FY25−$5.1Mn/a−$5.2M
Q1 FY25−$6.9Mn/a−$4M
Q4 FY24$3.7Mn/a−$2.4M
Q3 FY24$3.1Mn/a−$6.6M
Q2 FY24−$3.9Mn/a−$10.1M
Q1 FY24−$5.3Mn/a−$8.5M
Q4 FY23−$525Kn/a−$9.9M
Q3 FY23−$341Kn/a−$14.2M
Q2 FY23−$2.3Mn/a−$18.5M
Q1 FY23−$6.7Mn/a−$19M

Against its peers

Companies in Medical - Instruments & Supplies nearest LENSAR's size, closest first, today.

CompanyFree cash flow yield
LNSRLENSARn/m
KEQUKewaunee Scientific11.5%
APTAlpha Pro Tech10.3%
NEPHNephrosn/m
PDEXPro DEX3.4%
UTMDUtah Medical Products4.8%
INFUInfuSystem8.3%
EMBCEmbectan/m
TCMDTactile Systems Technology5.0%
MDXGMimedxn/m
MOVMovado10.2%
Peer median8.3%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on LENSAR

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.